FR2970869B1 - Utilisation du recepteur sigma-1 pour reguler l'expression des canaux ioniques au niveau post-transcriptionnel - Google Patents

Utilisation du recepteur sigma-1 pour reguler l'expression des canaux ioniques au niveau post-transcriptionnel

Info

Publication number
FR2970869B1
FR2970869B1 FR1150709A FR1150709A FR2970869B1 FR 2970869 B1 FR2970869 B1 FR 2970869B1 FR 1150709 A FR1150709 A FR 1150709A FR 1150709 A FR1150709 A FR 1150709A FR 2970869 B1 FR2970869 B1 FR 2970869B1
Authority
FR
France
Prior art keywords
sigma
receptor
post
expression
regulating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR1150709A
Other languages
English (en)
Other versions
FR2970869A1 (fr
Inventor
Olivier Soriani
Mauro Franck Borgese
Sonia Martial
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Original Assignee
Centre National de la Recherche Scientifique CNRS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS filed Critical Centre National de la Recherche Scientifique CNRS
Priority to FR1150709A priority Critical patent/FR2970869B1/fr
Priority to PCT/FR2012/050213 priority patent/WO2012104550A2/fr
Priority to EP12707835.0A priority patent/EP2670423A2/fr
Priority to US13/982,775 priority patent/US20130317226A1/en
Priority to CA2823870A priority patent/CA2823870A1/fr
Publication of FR2970869A1 publication Critical patent/FR2970869A1/fr
Application granted granted Critical
Publication of FR2970869B1 publication Critical patent/FR2970869B1/fr
Priority to US14/643,600 priority patent/US20150182550A1/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR1150709A 2011-01-31 2011-01-31 Utilisation du recepteur sigma-1 pour reguler l'expression des canaux ioniques au niveau post-transcriptionnel Expired - Fee Related FR2970869B1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
FR1150709A FR2970869B1 (fr) 2011-01-31 2011-01-31 Utilisation du recepteur sigma-1 pour reguler l'expression des canaux ioniques au niveau post-transcriptionnel
PCT/FR2012/050213 WO2012104550A2 (fr) 2011-01-31 2012-01-31 Utilisation du recepteur sigma-1 pour reguler l'expression des canaux ioniques au niveau posttranscriptionnel
EP12707835.0A EP2670423A2 (fr) 2011-01-31 2012-01-31 Utilisation du recepteur sigma-1 pour reguler l'expression des canaux ioniques au niveau posttranscriptionnel
US13/982,775 US20130317226A1 (en) 2011-01-31 2012-01-31 INHIBITORS OF THE INTERACTION OF THE SIGMA-1 RECEPTOR WITH hERG FOR USE IN THE TREATMENT OF CANCER
CA2823870A CA2823870A1 (fr) 2011-01-31 2012-01-31 Utilisation du recepteur sigma-1 pour reguler l'expression des canaux ioniques au niveau post-transcriptionnel
US14/643,600 US20150182550A1 (en) 2011-01-31 2015-03-10 INHIBITORS OF THE INTERACTION OF THE SIGMA-1 RECEPTOR WITH hERG FOR USE IN THE TREATMENT OF CANCER

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1150709A FR2970869B1 (fr) 2011-01-31 2011-01-31 Utilisation du recepteur sigma-1 pour reguler l'expression des canaux ioniques au niveau post-transcriptionnel

Publications (2)

Publication Number Publication Date
FR2970869A1 FR2970869A1 (fr) 2012-08-03
FR2970869B1 true FR2970869B1 (fr) 2013-09-06

Family

ID=44513223

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1150709A Expired - Fee Related FR2970869B1 (fr) 2011-01-31 2011-01-31 Utilisation du recepteur sigma-1 pour reguler l'expression des canaux ioniques au niveau post-transcriptionnel

Country Status (5)

Country Link
US (2) US20130317226A1 (fr)
EP (1) EP2670423A2 (fr)
CA (1) CA2823870A1 (fr)
FR (1) FR2970869B1 (fr)
WO (1) WO2012104550A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3413870T (pt) * 2016-02-11 2021-09-10 Sigmathera Sas Igmesina para utilização no tratamento de doença de alzheimer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0007842D0 (en) * 2000-03-31 2000-05-17 Spruce Barbara Sigma receptor ligands and their medical uses
AU2001263502A1 (en) * 2000-05-11 2001-11-20 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Potentiation of antineoplastic agents using sigma-2 ligands
CA2597341A1 (fr) * 2004-10-14 2006-04-20 Institut De Cardiologie De Montreal Depression de la fonction du canal potassique herg dans des cellules de mammiferes et applications a la regulation de la division de cellules cancereuses
WO2010015040A1 (fr) * 2008-08-07 2010-02-11 Powmri Ltd Thérapie et prévention d'une protéinopathie tdp-43
WO2010101649A2 (fr) * 2009-03-05 2010-09-10 Pablo Gastaminza Inhibition du récepteur sigma 1 en tant que nouvelle approche thérapeutique contre une infection par le virus de l'hépatite c

Also Published As

Publication number Publication date
US20150182550A1 (en) 2015-07-02
EP2670423A2 (fr) 2013-12-11
WO2012104550A3 (fr) 2012-10-26
WO2012104550A2 (fr) 2012-08-09
US20130317226A1 (en) 2013-11-28
CA2823870A1 (fr) 2012-08-09
FR2970869A1 (fr) 2012-08-03

Similar Documents

Publication Publication Date Title
EA201691368A1 (ru) ПИРРОЛИДИНИЛСУЛЬФОНОВЫЕ МОДУЛЯТОРЫ RORγ
PH12015501244A1 (en) Modulators of the retinoid-related orphan receptor gamma (ror-gamma) for use in the treatment of autoimmune and inflammatory diseases
EA201592103A2 (ru) Способы и композиции для усиления cd4+ регуляторных t-клеток
MX2017014375A (es) Moduladores del ccr2.
EA201491973A1 (ru) Новые соединения
EA201590586A1 (ru) Терапевтические наночастицы, включающие терапевтический агент, способы их получения и применения
MA52909A (fr) Procédés d'augmentation des taux de globules rouges et de traitement de la drépanocytose
MY180206A (en) Compounds and uses thereof for the modulation of hemoglobin
MX371344B (es) Antagonistas de il-4r para usarse en el tratamiento o prevención de asma persistente y asma severa.
EA201590655A8 (ru) Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений
EA201591426A1 (ru) Соединения и их применения для модуляции гемоглобина
EA201391332A1 (ru) Лиганды опиоидных рецепторов и способы их применения и получения
MY191087A (en) Compounds and uses thereof for the modulation of hemoglobin
PH12018500826B1 (en) Extracorporeal life support system and methods of use thereof
MY179105A (en) Methods of treating alzheimer's disease
FR2984743B1 (fr) Utilisation cosmetique du steviol, d'un derive glycoside du steviol, ou un de leurs isomeres pour stimuler, restaurer ou reguler le metabolisme des cellules de la peau et des semi-muqueuses.
MX355041B (es) Dominios de union a albumina consenso no naturales.
EA201890002A1 (ru) Положительные аллостерические модуляторы мускаринового рецептора м2
EA201591513A1 (ru) Терапевтическое применение антител к vegfr1 (варианты)
MA38253B1 (fr) Compositions comprenant de la vortioxétine et du donépézil
WO2014028668A3 (fr) Composés thérapeutiques activant les cellules souches
UA113966C2 (xx) Водна рідка фармацевтична композиція, яка містить арбекацин
FR2970869B1 (fr) Utilisation du recepteur sigma-1 pour reguler l'expression des canaux ioniques au niveau post-transcriptionnel
MX2015002694A (es) Permeabilidad de la celda de flujo y sistema de conductancia hidraulica.
MX2015002693A (es) Permeabilidad de celda de flujo y sistema de conductancia hidraulica.

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 6

ST Notification of lapse

Effective date: 20170929